Cover Image

Evaluation of the Pharmacokinetics and Exposure–Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease

Background and Objective: Dapagliflozin, a sodium-glucose co-transporter inhibitor, was originally developed as an oral glucose-lowering drug for the treatment of type 2 diabetes mellitus. Emerging data suggest that cardiovascular and kidney benefits extend to patients without diabetes. Limited phar...

Full description

Saved in:
Bibliographic Details
Main Authors: van der Aart-van der Beek, Annemarie B., Koomen, Jeroen V., Dekkers, Claire C.J., Barbour, Sean J., Boulton, David W., Gansevoort, Ron T., Greasley, Peter J., Abdul Gafor, Abdul Halim, Laverman, Gozewijn D., Li, Qiang, Lim, Soo Kun, Stevens, Jasper, Vervloet, Marc G., Singh, Sunita, Cattran, Daniel C., Reich, Heather N., Cherney, David Z.I., Heerspink, Hiddo J.L.
Format: Article
Published: Adis 2021
Subjects:
R Medicine
Online Access:http://eprints.um.edu.my/25966/
https://doi.org/10.1007/s40262-020-00956-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items